Literature DB >> 9605273

Vancomycin control measures at a tertiary-care hospital: impact of interventions on volume and patterns of use.

M V Singer1, R Haft, T Barlam, M Aronson, A Shafer, K E Sands.   

Abstract

OBJECTIVE: Evaluate vancomycin prescribing patterns in a tertiary-care hospital before and after interventions to decrease vancomycin utilization.
DESIGN: Before/after analysis of interventions to limit vancomycin use.
SETTING: 420-bed academic tertiary-care center.
INTERVENTIONS: Educational efforts began August 10, 1994, and involved lectures to medical house staff followed by mailings to all physicians and posting of guidelines for vancomycin use on hospital information systems. Active interventions began November 15, 1994, and included automatic stop orders for vancomycin at 72 hours, alerts attached to the medical record, and, for 2 weeks only, computer alerts to physicians following each vancomycin order. Parenteral vancomycin use was estimated from the hospital pharmacy database of all medication orders. Records of a random sample of 344 patients receiving vancomycin between May 1, 1994, and April 30, 1995, were reviewed for an indication meeting published guidelines.
RESULTS: Vancomycin prescribing decreased by 22% following interventions, from 8.5 to 6.8 courses per 100 discharges (P<.05). The estimated proportion of vancomycin ordered for an indication meeting published guidelines was 36.6% overall, with no significant change following interventions. However, during the 2 weeks that computer alerts were in place, 60% of vancomycin use was for an approved indication.
CONCLUSIONS: Parenteral vancomycin prescribing decreased significantly following interventions, but the majority of orders still were not for an indication meeting published guidelines. Further improvement in the appropriateness of vancomycin prescribing potentially could be accomplished by more aggressive interventions, such as computer alerts, or by targeting specific aspects of prescribing patterns.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9605273     DOI: 10.1086/647803

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  8 in total

1.  Molecular epidemiology of vancomycin-resistant Enterococcus faecium in a large urban hospital over a 5-year period.

Authors:  W E Bischoff; T M Reynolds; G O Hall; R P Wenzel; M B Edmond
Journal:  J Clin Microbiol       Date:  1999-12       Impact factor: 5.948

2.  [Effects of restrictions on use of vancomycin in a German university hospital].

Authors:  T Glück; H J Linde; E Wiegrebe; N Lehn; M Reng; J Schölmerich
Journal:  Med Klin (Munich)       Date:  2000-02-15

3.  Decision support and safety of clinical environments.

Authors:  A H Morris
Journal:  Qual Saf Health Care       Date:  2002-03

Review 4.  Clinical and economic considerations of empirical antibacterial therapy of febrile neutropenia in cancer.

Authors:  G Dranitsaris
Journal:  Pharmacoeconomics       Date:  1999-10       Impact factor: 4.981

5.  Curtailing unnecessary vancomycin usage in a hospital with high rates of methicillin resistant Staphylococcus aureus infections.

Authors:  C R Kumana; T Y Ching; Y Kong; E C Ma; M Kou; R A Lee; V C Cheng; S S Chiu; W H Seto
Journal:  Br J Clin Pharmacol       Date:  2001-10       Impact factor: 4.335

6.  Real-time PCR testing for mecA reduces vancomycin usage and length of hospitalization for patients infected with methicillin-sensitive staphylococci.

Authors:  David T Nguyen; Ellen Yeh; Sharon Perry; Robert F Luo; Benjamin A Pinsky; Betty P Lee; Deepak Sisodiya; Ellen Jo Baron; Niaz Banaei
Journal:  J Clin Microbiol       Date:  2010-01-13       Impact factor: 5.948

7.  Vancomycin and home health care.

Authors:  Thomas G Fraser; Valentina Stosor; Qiong Wang; Anne Allen; Teresa R Zembower
Journal:  Emerg Infect Dis       Date:  2005-10       Impact factor: 6.883

8.  Vancomycin-resistant enterococcus outbreak in a pediatric intensive care unit: report of successful interventions for control and prevention.

Authors:  F Carmona; S I Prado; M F I Silva; G G Gaspar; F Bellissimo-Rodrigues; R Martinez; A K Matsuno; A P C P Carlotti
Journal:  Braz J Med Biol Res       Date:  2012-01-26       Impact factor: 2.590

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.